KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis.

Jan Oscarsson, Monika Huhn, Yunyun Jiang, Ingrid Gause-Nilsson, Stephen D Wiviott, Filipe A Moura, John P H Wilding, Simona Cernea, Luc Van Gaal, Avivit Cahn, Deepak L Bhatt, Peter A Johansson, C David Sjöström

Diabetes Obes Metab 28(7) 6142-6150

PMID42046405
PMCIDPMC13243968
DOI10.1111/dom.70820
发表日期2026-04-28
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:森林图/亚组分析图;FIGURE 3:AI 判定为 other。
摘要

摘要

AIMS: The fibrosis-4 (FIB-4) score is used to identify risk of advanced liver fibrosis. This post hoc analysis investigated its prognostic value for cardiovascular (CV) outcomes and its relevance to the effects of dapagliflozin. MATERIALS AND METHODS: DECLARE-TIMI 58 was a randomised, placebo-controlled phase 3 trial investigating dapagliflozin in patients with type 2 diabetes (T2D) and either atherosclerotic cardiovascular disease (ASCVD) or high ASCVD risk. Participants were stratified by baseline FIB-4 scores (< 1.30, 1.30 to < 2.67, and ≥ 2.67). Hazard ratios (HRs) and 95% confidence intervals (CIs) for dapagliflozin versus placebo were calculated for the two primary outcomes (major adverse cardiovascular events [MACE] and the composite of CV death and hospitalisation for heart failure [HHF]). RESULTS: Of 17 160 patients enrolled, 16 361 were included (median follow-up of 4.2 years). Distribution across FIB-4 categories was: < 1.30, n = 9084 (55.5%); 1.30 to < 2.67, n = 6556 (40.7%); and ≥ 2.67, n = 621 (3.8%), with similar ASCVD prevalence across groups (40%-43%). In the placebo arm, the ≥ 2.67 FIB-4 group had the highest event rates for MACE, HHF, CV death, and all-cause death. MACE HRs (95% CIs) for dapagliflozin versus placebo were 0.95 (0.83-1.10), 0.92 (0.79-1.08), and 0.61 (0.38-0.97) across ascending FIB-4 groups. For the CV death and HHF composite endpoint, they were 0.81 (0.67-0.98), 0.90 (0.73-1.10), and 0.50 (0.28-0.90). Dapagliflozin reduced aspartate aminotransferase and alanine aminotransferase levels compared with placebo. CONCLUSION: Highest FIB-4 scores were associated with increased CV risk in patients with T2D. Dapagliflozin reduced CV risk across FIB-4 categories without significant interactions.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Patients included in the analysis. Abbreviation: FIB‐4, fibrosis‐4 score.
非 KM Figure
FIGURE 2FIGURE 2 Hazard ratios for CV outcomes and all‐cause death. Abbreviations: CI, confidence interval; CV, cardiovascular; FIB‐4, fibrosis‐4 score; HHF, hospitalisation for heart failure; MACE, major adverse cardiovascular events.
非 KM Figure
FIGURE 3FIGURE 3 Change in LS mean from baseline in (A) AST levels and (B) ALT levels. Whiskers represent 95% confidence intervals. * p < 0.05 for comparison between dapagliflozin and placebo. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; LS, least‐squares.
非 KM Figure